Discovering inhibitors of gain-of-function Phospholipase C gamma1 for T-cell lymphomas

This proposal is aimed at creating medicines that can control a protein called Phospholipase Cgamma1, for use in the treatment of a subtype of blood cancers, known as T-cell lymphomas.

It is based on clinical insight provided by our team, including those treating patients with this disease and the recognition of a need for improved therapies. We have long-term expertise on the proposed target molecule.

We believe we have established a set of interconnected experimental and screening approaches that will provide the route to new treatment options, and would now like to turn these advances into a medicine, with the help of the access to the AstraZeneca screening collection to start our drug discovery efforts.

Although this proposal focuses on T-cell lymphomas, drugs obtained for this purpose will be also useful for a range of other diseases caused by deregulation of the same target.